Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | CCR1 | P32246 | 12/20 | 0.55 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.54 |
| ▸ | CCR5 | P51681 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23009569 | 0.85 | NPC1 (0.53) | — | |
| SCHEMBL13588778 | 0.84 | KCNH2 (0.64) | ADAMTS5KCNH2HRH3CCR1 | |
| SCHEMBL17130353 | 0.83 | EPHX2 (0.63) | ADAMTS5CCR1 | |
| SCHEMBL15045186 | 0.82 | KCNH2 (0.61) | ADAMTS5KCNH2HRH3CCR1 | |
| SCHEMBL14672010 | 0.80 | HRH3 (0.56) | ADAMTS5KCNH2HRH3CCR1SLC18A3 | |
| SCHEMBL23138269 | 0.79 | KCNH2 (0.58) | ADAMTS5KCNH2HRH3CCR1SLC18A3 | |
| SCHEMBL19702754 | 0.79 | ADAMTS5 (0.51) | ADAMTS5KCNH2HRH3CCR1 | |
| SCHEMBL22063764 | 0.79 | ADAMTS5 (0.51) | ADAMTS5KCNH2HRH3CCR1 | |
| SCHEMBL4034093 | 0.78 | ALDH1A1 (0.57) | ADAMTS5KCNH2HRH3SLC18A3 | |
| SCHEMBL31487378 | 0.78 | RBP4 (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220098214-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING FIBROSIS | YALE UNIVERSITY | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098214-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING FIBROSIS | DUSP5, DUSP4, DUSP6 | ADAMTS5 612/4885KCNH2 4443/4885HRH3 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.